MedTrace Logo

Recovery From ICUAW Following Severe Respiratory and Cardiac Failure

NCT03753412 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2026-01-07

No results posted yet for this study

Summary

To observe and identify determinants of recovery from intensive care unit-acquired weakness (ICUAW) following a severe cardiorespiratory failure requiring extra-corporeal membrane oxygenation (ECMO). Additionally, to discover the effects of ICUAW on physical function and health-related quality of life (HRQoL) after critical illness. CLEVERER is a clinical observational pilot study.

Conditions

  • Intensive Care Unit Syndrome
  • Intensive Care Neuropathy
  • Intensive Care (ICU) Myopathy
  • Acute Respiratory Distress Syndrome
  • Cardiac Failure
  • Respiratory Failure
  • Critical Illness Myopathy

Sponsors & Collaborators

  • Queen Mary University of London

    collaborator OTHER

  • Barts & The London NHS Trust

    lead OTHER

Principal Investigators

  • Mark Griffiths, PhD FRCP · Substantive Employee and primary supervisor to PhD student

  • Julie Sanders, MSc, PhD · Director of research and supervisor to PhD student

  • Ashley Thomas, MSc · Substantive employee and PhD student

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-04-09
Primary Completion
2026-09-26
Completion
2026-09-26

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03753412 on ClinicalTrials.gov